C
02616
CStone Pharmaceuticals
8.33
1.43+20.72%Closed16:08 03/27 HKT
OPEN/PREV CLOSE6.800/6.900
TODAY RANGE6.780-8.470
VOL76.36M
MARKET CAP12.30B
52 WEEK RANGE2.030-13.150
AVG VOL (3M)11.66M
% TURNOVER5.17%
TURNOVER613.53M
P/E (TTM)-25.412
% RANGE24.49%
EPS(TTM)-0.328
P/E(FORWARD)-113.026
P/B18.007
BVPS0.463
DIVIDEND--
P/S41.197
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP12.30B
SHARES OUTSTANDING1.48B
NEXT EARNINGS--
FREE FLOAT1.48B
LOT SIZE500
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·19h ago
CStone Pharmaceuticals (HKG:2616) Just Reported And Analysts Have Been Cutting Their Estimates
Simply Wall St·2d ago
CStone Pharmaceuticals (SEHK:2616) Loss Swing To C¥270 Million Tests Bullish Growth Narratives
Simply Wall St·03/09 06:25
CStone Pharmaceuticals (SEHK:2616) Valuation Check After New UK Approval For Sugemalimab In Stage III Lung Cancer
Simply Wall St·03/06 17:24
Expanded UK and EU Sugemalimab Approvals Could Be A Game Changer For CStone Pharmaceuticals (SEHK:2616)
Simply Wall St·03/02 04:29
CStone Pharmaceuticals (SEHK:2616) Valuation After New Sugemalimab Indication And US Phase II Trial Clearance
Reuters·02/23 00:10
CSTONE ANNOUNCES MHRA APPROVAL IN UK FOR SUGEMALIMAB IN STAGE III NSCLC
Reuters·02/23 00:06
UK MHRA approves CStone’s sugemalimab for unresectable stage III NSCLC
Simply Wall St·02/16 13:17
CStone Pharmaceuticals (SEHK:2616) Valuation After FDA Clearance For Phase II Immunotherapy Trial
Reuters·02/16 00:00
CStone Pharmaceuticals Receives FDA Clearance for Phase II Trial of CS2009
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.